Nanoparticle-Delivered Peptide Provides Long-Lasting Nerve Pain Relief With a Single Injection in Rats | Research

The takeaway

A peptide inhibitor delivered via nanoparticles directly to nerves produced potent, long-lasting pain relief from a single injection in a rat neuropathic pain model, outperforming the free peptide.

Single injection, lasting relief
One intraneural injection of peptide-loaded nanoparticles outperformed the free peptide for neuropathic pain relief in rats, with the nanoparticles providing sustained peptide release directly at the nerve.

What the researchers found

The CRPPNs (CBD3A6K-RhB-loaded PEG-PLGA nanoparticles) showed uniform morphology, high encapsulation efficiency, and sustained peptide release in vitro. When internalized by dorsal root ganglion (DRG) neurons, they significantly inhibited calcium influx and CGRP release — two key drivers of neuropathic pain signaling.

In a rat chronic constriction injury (CCI) model of the sciatic nerve, a single intraneural injection of CRPPNs produced potent and long-lasting anti-allodynic (reduced sensitivity to touch) and anti-hyperalgesic (reduced pain response) effects that were superior to the free peptide. The mechanism involved downregulation of CaV2.2 expression in both the dorsal root ganglion and spinal cord. Comprehensive biosafety evaluation confirmed excellent biocompatibility.

Why it matters

Chronic neuropathic pain affects millions of people and current treatments — opioids, gabapentin, pregabalin — have significant side effects, limited efficacy, and/or addiction risk. A peptide-based therapy delivered directly to the nerve could provide long-lasting relief from a single injection while avoiding systemic side effects. The non-opioid mechanism (blocking calcium channel interactions rather than opioid receptors) is particularly attractive given the ongoing opioid crisis.

How the study worked

Researchers engineered a modified peptide inhibitor (CBD3A6K-RhB) with enhanced binding affinity for the CaV2.2-CRMP2 interaction. The peptide was encapsulated in PEG-PLGA nanoparticles using microfluidic technology. In vitro testing assessed nanoparticle morphology, encapsulation efficiency, release kinetics, neuronal uptake, calcium influx inhibition, and CGRP release in DRG neurons. In vivo efficacy was tested in a rat CCI model of the sciatic nerve, with a single intraneural injection. Biosafety was comprehensively evaluated.

What this study cannot tell us

This is a preclinical study in rats, and pain models in rodents have historically translated poorly to human clinical outcomes. The intraneural injection route, while effective for targeted delivery, requires precision placement that may be technically challenging in clinical practice. Long-term effects beyond the study period were not reported. Only one pain model (CCI) was tested. The specific duration of pain relief was not detailed in the abstract, and whether repeated injections would be needed is unknown.

How to read the evidence

This is a well-designed preclinical study with thorough in vitro characterization, in vivo efficacy in a standard neuropathic pain model, and biosafety evaluation. However, all data is from rat models, and translation to human pain management would require extensive clinical development.

When this study was published

Published in 2026, this is an extremely recent study representing the current frontier of peptide nanomedicine for pain management.

The bigger picture

This study sits at the intersection of three hot areas in pain research: peptide therapeutics, targeted nanoparticle delivery, and non-opioid pain management. The CaV2.2 calcium channel has long been recognized as a pain target (ziconotide, derived from cone snail venom, targets a related channel), but delivery challenges have limited peptide-based approaches. By combining a rationally designed peptide with nanoparticle technology and intraneural delivery, this study offers a blueprint for next-generation pain treatments that could bypass the need for systemic drug exposure.

Questions still open

How long does the pain relief last from a single injection, and would repeated treatments be safe and effective?
Could ultrasound-guided intraneural injection make this approach practical for clinical use in human neuropathic pain?
How does this peptide-nanoparticle approach compare in efficacy and safety to existing non-opioid pain treatments like ziconotide?

Common questions

How does this peptide pain treatment work differently from opioids?

Instead of activating opioid receptors in the brain (which causes pain relief but also addiction and side effects), this peptide blocks a specific calcium channel interaction (CaV2.2-CRMP2) in nerve cells that transmits pain signals. It targets the source of the pain signal at the nerve level rather than masking pain perception in the brain.

Why use nanoparticles instead of injecting the peptide directly?

Free peptides break down quickly in the body, providing only brief pain relief. By packaging the peptide inside biodegradable nanoparticles, the treatment slowly releases the active peptide over an extended period, providing long-lasting relief from a single injection. The nanoparticles also help the peptide get into nerve cells more effectively.

Read the original research

Intraneural delivery of CBD3A6K-RhB via PEG-PLGA nanoparticles for neuropathic pain therapy.

Journal of controlled release : official journal of the Controlled Release Society, 392, 114662

View on PubMed ↗Publisher’s paper ↗

Citation

Zhang, Zhihao; Li, Hao; Liu, Jiarui; Shen, Nana; Zhu, Zhongze; Qi, Xiaoying; Meng, Ming; Wang, Weijiang; Wu, Futong; Qi, Yunkun; Cao, Yong; Ma, Qingming; Xiang, Hongfei. (2026). Intraneural delivery of CBD3A6K-RhB via PEG-PLGA nanoparticles for neuropathic pain therapy.. Journal of controlled release : official journal of the Controlled Release Society, 392, 114662. https://doi.org/10.1016/j.jconrel.2026.114662